DUBLIN--(BUSINESS WIRE)--The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for CAR T-cell Therapy was estimated ...
The hits seem to be coming from all directions lately. Falls in the facility have increased over the past quarter. Several long-term care residents have triggered for significant weight loss on the ...
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with ...
MaxCyte, Inc. announced a strategic platform license agreement with TG Therapeutics, a biopharmaceutical company specializing in treatments for B-cell diseases. Under this agreement, TG Therapeutics ...
COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, a leading Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has announced a strategic partnership with ...
HOUSTON--(BUSINESS WIRE)-- U.S. Physical Therapy, Inc. (“USPH”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention ...
JMP Securities initiated coverage on U.S. Physical Therapy, Inc. (NYSE:USPH), an operator outpatient physical therapy provider with more than 750 owned or managed clinics across 43 states. JMP is ...
Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its Board of Directors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results